[go: up one dir, main page]

MA38175A1 - Lactames fusionnés à un aryle et hétéroaryle - Google Patents

Lactames fusionnés à un aryle et hétéroaryle

Info

Publication number
MA38175A1
MA38175A1 MA38175A MA38175A MA38175A1 MA 38175 A1 MA38175 A1 MA 38175A1 MA 38175 A MA38175 A MA 38175A MA 38175 A MA38175 A MA 38175A MA 38175 A1 MA38175 A1 MA 38175A1
Authority
MA
Morocco
Prior art keywords
heteroaryl
aryl
compounds
salts
lactams
Prior art date
Application number
MA38175A
Other languages
English (en)
Other versions
MA38175B1 (fr
Inventor
Martin Paul Edwards
Robert Arnold Kumpf
Pei-Pei Kung
Indrawan James Mcalpine
Sacha Ninkovic
Eugene Yuanjin Rui
Scott Channing Sutton
John Howard Tatlock
Martin James Wythes
Luke Raymond Zehnder
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA38175A1 publication Critical patent/MA38175A1/fr
Publication of MA38175B1 publication Critical patent/MA38175B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Cette invention concerne des composés de formule générale (i), des sels pharmaceutiquement acceptables de ceux-ci, des compositions pharmaceutiques contenant lesdits composés et sels, et des méthodes d'utilisation desdits composés, sels et compositions pour traiter une croissance cellulaire anormale, y compris le cancer. Dans la formule générale (i), r
MA38175A 2012-12-21 2013-12-05 Lactames fusionnés à un aryle et hétéroaryle MA38175B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261740596P 2012-12-21 2012-12-21
PCT/IB2013/060682 WO2014097041A1 (fr) 2012-12-21 2013-12-05 Lactames fusionnés à un aryle et hétéroaryle

Publications (2)

Publication Number Publication Date
MA38175A1 true MA38175A1 (fr) 2018-08-31
MA38175B1 MA38175B1 (fr) 2018-11-30

Family

ID=49917684

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38175A MA38175B1 (fr) 2012-12-21 2013-12-05 Lactames fusionnés à un aryle et hétéroaryle

Country Status (47)

Country Link
US (3) US9040515B2 (fr)
EP (2) EP3339303B9 (fr)
JP (1) JP5909308B2 (fr)
KR (1) KR101712441B1 (fr)
CN (1) CN104870435B (fr)
AP (1) AP2015008574A0 (fr)
AR (1) AR094174A1 (fr)
AU (1) AU2013365908C1 (fr)
BR (1) BR112015014678B1 (fr)
CA (1) CA2893339C (fr)
CL (1) CL2015001733A1 (fr)
CR (2) CR20200273A (fr)
CU (1) CU24414B1 (fr)
CY (2) CY1119883T1 (fr)
DK (2) DK3339303T3 (fr)
DO (1) DOP2015000157A (fr)
EA (1) EA028317B1 (fr)
EC (1) ECSP15031579A (fr)
ES (2) ES2658974T3 (fr)
GE (1) GEP201706718B (fr)
GT (1) GT201500190A (fr)
HK (1) HK1208866A1 (fr)
HR (2) HRP20180060T1 (fr)
HU (2) HUE038238T2 (fr)
IL (1) IL239520B (fr)
LT (2) LT3339303T (fr)
MA (1) MA38175B1 (fr)
MD (1) MD4664C9 (fr)
ME (2) ME03793B (fr)
MX (2) MX2015008058A (fr)
MY (2) MY176307A (fr)
NO (1) NO2961649T3 (fr)
NZ (1) NZ708801A (fr)
PE (1) PE20151090A1 (fr)
PH (1) PH12015501367B1 (fr)
PL (2) PL3339303T3 (fr)
PT (2) PT3339303T (fr)
RS (2) RS60582B9 (fr)
SG (1) SG11201504076XA (fr)
SI (2) SI2935238T1 (fr)
TN (1) TN2015000281A1 (fr)
TR (1) TR201802791T4 (fr)
TW (1) TWI546293B (fr)
UA (1) UA111305C2 (fr)
UY (2) UY35225A (fr)
WO (1) WO2014097041A1 (fr)
ZA (1) ZA201504437B (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013075084A1 (fr) 2011-11-18 2013-05-23 Constellation Pharmaceuticals Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées
EP2812001B1 (fr) 2012-02-10 2017-06-14 Constellation Pharmaceuticals, Inc. Modulateurs d'enzymes de modification par méthylation, leurs compositions et utilisations
AR092742A1 (es) * 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
EP2935303B1 (fr) 2012-12-21 2021-02-17 Janssen BioPharma, Inc. 4'-fluoro-nucléosides, 4'-fluoro-nucléotides et leurs analogues pour le traitement du vhc
UA111305C2 (uk) * 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
EP2970305B1 (fr) 2013-03-15 2017-02-22 Constellation Pharmaceuticals, Inc. Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées
EP3033334A1 (fr) 2013-08-15 2016-06-22 Constellation Pharmaceuticals, Inc. Dérivés d'indole utilisés en tant que modulateurs d'enzymes de modification du méthyle, compositions et utilisations associées
EA031892B1 (ru) * 2014-06-17 2019-03-29 Пфайзер Инк. Замещенные дигидроизохинолиноновые соединения для лечения аномального клеточного роста, ассоциированного с активностью ezh2
WO2015193768A1 (fr) * 2014-06-17 2015-12-23 Pfizer Inc. Lactames à fusion aryle à utiliser en tant que modulateurs ezh2
CN107148419A (zh) * 2014-10-28 2017-09-08 葛兰素史密斯克莱知识产权（第2 号）有限公司 Zeste增强子同源物2抑制剂
AR102767A1 (es) 2014-12-05 2017-03-22 Lilly Co Eli Inhibidores de ezh2
EP3236962A2 (fr) 2014-12-23 2017-11-01 University of Copenhagen Traitement du cancer par inhibition de l'activité de l'ezh2
EP3683213B1 (fr) * 2015-03-27 2022-10-12 Syngenta Participations Ag Intermédiaire pour la préparation de dérivés hétérobicycliques microbiocides
UY36758A (es) * 2015-06-30 2016-12-30 Glaxosmithkline Ip No 2 Ltd Inhibidores del potenciador del homólogo zeste 2
TW201718598A (zh) * 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑
US10577350B2 (en) 2015-08-28 2020-03-03 Constellation Pharmaceuticals, Inc. Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide
PL3378859T3 (pl) 2015-11-19 2020-04-30 Jiangsu Hengrui Medicine Co., Ltd. Pochodna benzofuranu, sposób jej wytwarzania i jej zastosowanie w medycynie
AU2017260854B2 (en) 2016-05-05 2020-01-30 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of Zeste Homolog 2 inhibitors
EP3529242A1 (fr) 2016-10-19 2019-08-28 Constellation Pharmaceuticals, Inc. Synthèse d'inhibiteurs d'ezh2
WO2018086589A1 (fr) * 2016-11-11 2018-05-17 上海海雁医药科技有限公司 Dérivés d'isoquinoléine 1,5,7-tri-substitués, leur préparation et leur utilisation dans des médicaments
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
RU2762893C2 (ru) 2017-05-18 2021-12-23 Цзянсу Хэнжуй Медсин Ко., Лтд. Применение ингибитора ezh2 в комбинации с ингибитором btk в получении лекарственного средства для лечения опухоли
BR112019021023A2 (pt) 2017-05-18 2020-05-05 Jiangsu Hengrui Medicine Co cristal de base livre de derivado de benzofurano e método de preparação.
CN106977483A (zh) * 2017-06-02 2017-07-25 遵义医学院 一种二氟烷基取代的黄酮醇、异黄酮醇和香豆素类化合物的合成方法
JP7201400B2 (ja) 2017-11-14 2023-01-10 ファイザー・インク Ｅｚｈ２阻害剤組合せ療法
PT4043466T (pt) 2018-01-31 2024-10-14 Mirati Therapeutics Inc Inibidores de prc2
CN112533581B (zh) * 2018-06-07 2024-08-30 密歇根大学董事会 Prc1抑制剂及用其进行治疗的方法
CN112399857A (zh) 2018-07-09 2021-02-23 盲人庇护基金会 Prc2亚单位的抑制治疗眼失调
WO2020086857A1 (fr) * 2018-10-24 2020-04-30 Vanderbilt University Modulateurs et inhibiteurs de wdr5
CN111320582A (zh) * 2018-12-17 2020-06-23 江苏恩华药业股份有限公司 一种类酰胺类衍生物及其中间体的制备方法
KR102689665B1 (ko) * 2019-02-19 2024-07-31 한미약품 주식회사 신규한 헤테로트리시클릭 유도체 화합물 및 이의 용도
KR102386403B1 (ko) * 2020-08-13 2022-04-15 한미약품 주식회사 신규한 디옥솔로이소퀴놀린온 유도체 화합물 및 이의 용도
CA3165787C (fr) * 2020-08-13 2023-06-06 Seung Hyun Jung Nouveaux derives de dioxoloisoquinolinone et leur utilisation
CN116457348B (zh) * 2021-02-26 2024-11-26 南京迈晟科技有限责任公司 Ezh2抑制剂及其用途
WO2024126650A1 (fr) 2022-12-15 2024-06-20 Syngenta Crop Protection Ag Nouveaux composés bicycliques-carboxamide utiles en tant que pesticides
CN118978498A (zh) * 2024-10-22 2024-11-19 浙江雅辰药物科技股份有限公司 一种5-羟甲基四氢呋喃-3-醇的制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3846412A (en) 1971-03-18 1974-11-05 Lepetit Spa Dihydro-2-amino-isoquinolines and their derivatives
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (fr) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing-gum contenant des agents medicamenteux actifs
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
US20070093515A1 (en) 2005-08-16 2007-04-26 Arrington Mark P Phosphodiesterase 10 inhibitors
US20100113415A1 (en) 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
WO2011103016A2 (fr) 2010-02-19 2011-08-25 The Regents Of The University Of Michigan Compositions et méthodes d'inhibition d'ezh2
US8846935B2 (en) 2010-05-07 2014-09-30 Glaxosmithkline Llc Indazoles
WO2012005805A1 (fr) 2010-05-07 2012-01-12 Glaxosmithkline Llc Aza-indazoles
LT2566327T (lt) 2010-05-07 2017-05-25 Glaxosmithkline Llc Indolai
BR112013005806B1 (pt) 2010-09-10 2022-05-10 Epizyme, Inc Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2
WO2012035078A1 (fr) 2010-09-16 2012-03-22 Novartis Ag Inhibiteurs de la 17α-hydroxylase/c17,20-lyase
US20130310379A1 (en) 2010-11-19 2013-11-21 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
EP2681216B1 (fr) * 2011-02-28 2017-09-27 Epizyme, Inc. Composés hétéroaryles bicycliques substitués condensés en 6,5
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TWI598336B (zh) 2011-04-13 2017-09-11 雅酶股份有限公司 經取代之苯化合物
WO2013049770A2 (fr) 2011-09-30 2013-04-04 Glaxosmithkline Llc Méthodes de traitement du cancer
US9562041B2 (en) 2012-05-16 2017-02-07 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
JP6254169B2 (ja) 2012-09-28 2017-12-27 ファイザー・インク ベンズアミドおよびヘテロベンズアミド化合物
EP2935303B1 (fr) 2012-12-21 2021-02-17 Janssen BioPharma, Inc. 4'-fluoro-nucléosides, 4'-fluoro-nucléotides et leurs analogues pour le traitement du vhc
FR3000059A1 (fr) 2012-12-21 2014-06-27 Saint Gobain Placo Composition pour plaques de platre et produits obtenus
FR3000065A1 (fr) 2012-12-21 2014-06-27 Univ Lille Ii Droit & Sante Composes bicycliques ayant une activite potentialisatrice de l'activite d'un antibiotique actif contre les mycobacteries-composition et produit pharmaceutiques comprenant de tels composes
EP2934567B9 (fr) 2012-12-21 2018-08-22 Sanofi Dérivés de exendin-4 en tant que glp1/gip double ou agonistes trigonaux de glp1/gip/glucagon
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
MX358684B (es) 2012-12-21 2018-08-31 Hoffmann La Roche Peptidos como agonistas de oxitocina.
PL3608325T3 (pl) 2012-12-21 2022-11-07 Gilead Sciences, Inc. Policykliczne związki karbamoilopirydonu i ich zastosowanie farmaceutyczne
BR112015014590B1 (pt) 2012-12-21 2022-12-20 Epizyme, Inc Composto, composição farmacêutica e estojo ou farmacêutico empacotado
LT2935248T (lt) 2012-12-21 2018-04-10 Plexxikon Inc. Kinazės moduliavimo junginiai ir būdai bei indikacijos
EA031892B1 (ru) 2014-06-17 2019-03-29 Пфайзер Инк. Замещенные дигидроизохинолиноновые соединения для лечения аномального клеточного роста, ассоциированного с активностью ezh2

Also Published As

Publication number Publication date
CN104870435A (zh) 2015-08-26
BR112015014678A2 (pt) 2017-07-11
NZ708801A (en) 2018-08-31
PL2935238T3 (pl) 2018-05-30
HUE050009T2 (hu) 2020-11-30
PE20151090A1 (es) 2015-08-07
US9040515B2 (en) 2015-05-26
BR112015014678B1 (pt) 2021-12-07
KR20150100823A (ko) 2015-09-02
PH12015501367B1 (en) 2018-08-03
PT3339303T (pt) 2020-07-30
US20140179667A1 (en) 2014-06-26
LT3339303T (lt) 2020-09-10
ES2808987T9 (es) 2021-11-29
KR101712441B1 (ko) 2017-03-07
HK1208866A1 (en) 2016-03-18
CL2015001733A1 (es) 2015-10-23
RS60582B9 (sr) 2021-09-30
AU2013365908C1 (en) 2018-01-25
CR20200273A (es) 2020-09-23
ES2808987T3 (es) 2021-03-02
GEP201706718B (en) 2017-08-10
EA201590879A1 (ru) 2015-12-30
HUE038238T2 (hu) 2018-10-29
EP2935238B1 (fr) 2017-12-27
TWI546293B (zh) 2016-08-21
EP3339303B1 (fr) 2020-06-24
MX2020002924A (es) 2020-07-22
GT201500190A (es) 2016-01-21
AR094174A1 (es) 2015-07-15
JP5909308B2 (ja) 2016-04-26
AP2015008574A0 (en) 2015-07-31
PL3339303T3 (pl) 2021-01-25
SI2935238T1 (en) 2018-04-30
US10246433B2 (en) 2019-04-02
ZA201504437B (en) 2016-07-27
UA111305C2 (uk) 2016-04-11
DK3339303T3 (da) 2020-08-10
EP2935238A1 (fr) 2015-10-28
MD20150052A2 (ro) 2015-12-31
IL239520B (en) 2018-05-31
AU2013365908A1 (en) 2015-06-11
HRP20201194T2 (hr) 2021-09-17
IL239520A0 (en) 2015-08-31
UY38712A (es) 2020-06-30
SG11201504076XA (en) 2015-06-29
TR201802791T4 (tr) 2018-03-21
MX2015008058A (es) 2015-10-30
CY1123237T1 (el) 2021-10-29
SI3339303T1 (sl) 2020-09-30
ECSP15031579A (es) 2017-08-31
CR20150279A (es) 2015-09-03
US20170233368A1 (en) 2017-08-17
PT2935238T (pt) 2018-02-09
WO2014097041A1 (fr) 2014-06-26
CY1119883T1 (el) 2018-06-27
RS56815B1 (sr) 2018-04-30
MD4664B1 (ro) 2019-12-31
CA2893339C (fr) 2017-06-13
ES2658974T3 (es) 2018-03-13
ME03793B (fr) 2021-04-20
CN104870435B (zh) 2016-12-07
EA028317B1 (ru) 2017-11-30
RS60582B1 (sr) 2020-08-31
CU20150062A7 (es) 2015-11-27
EP3339303A1 (fr) 2018-06-27
TW201446753A (zh) 2014-12-16
CU24414B1 (es) 2019-05-03
JP2016507497A (ja) 2016-03-10
CA2893339A1 (fr) 2014-06-26
TN2015000281A1 (fr) 2016-10-03
ME02980B (fr) 2018-10-20
LT2935238T (lt) 2018-02-26
NO2961649T3 (fr) 2018-02-17
DOP2015000157A (es) 2015-11-30
HRP20201194T1 (hr) 2020-11-13
DK2935238T3 (en) 2018-01-22
US20150175572A1 (en) 2015-06-25
MY176307A (en) 2020-07-28
PH12015501367A1 (en) 2015-09-02
AU2013365908B2 (en) 2017-07-20
MD4664C9 (ro) 2020-07-31
HRP20180060T1 (hr) 2018-02-23
MY192259A (en) 2022-08-12
UY35225A (es) 2014-07-31
EP3339303B9 (fr) 2021-07-21
MA38175B1 (fr) 2018-11-30

Similar Documents

Publication Publication Date Title
MA38175B1 (fr) Lactames fusionnés à un aryle et hétéroaryle
MA40225A (fr) Composés dihydroisoquinolinone substitués
MA45920A (fr) Inhibiteurs de pyridopyrimidinone cdk2/4/6
MA38138A1 (fr) Dérivés inédits de quinolone
PH12016501440A1 (en) Novel heterocyclic compounds
UA111770C2 (uk) Інгібітори бромдомену
MA37142A3 (fr) Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine
MX2014012695A (es) Derivados de isoindolona.
MA37400B1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
MA39211B1 (fr) Composés tricycliques comme agents anti-cancers
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
MA39995B1 (fr) Composés destinés à traiter l'amyotrophie spinale
EA025302B8 (ru) Модуляторы кальциевого канала, активируемого высвобождением кальция, представляющие собой производные пиразола, и способы лечения немелкоклеточного рака легких
MX2013012776A (es) Inhibidores de la tirosina cinasa de bazo que contienen aminopiridina.
MA47301B1 (fr) Inhibiteurs sélectifs de jak1
TN2016000188A1 (fr) Derives de purines 2,6-substitues et leur utilisation dans le traitement de troubles proliferatifs.
MA37886B1 (fr) Nouvelles pyridinones bicycliques
MA38999A1 (fr) Nouveaux composés hétérocycliques
MA38240B1 (fr) Nouveaux composes dimeres substitues antagonistes de l'iap utiles pour le traitement du cancer, de preference des tumeurs solides
MA39152B1 (fr) Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine
SA518390920B1 (ar) مركبات فينوكسي أسيتاميد معالجة بإضافة حلقة
MA34098B1 (fr) Utilisation de nouveaux inhibiteurs pan-cdk pour le traitement de tumeurs
MA38679B1 (fr) Modulateurs du récepteur de cxcr7
UA107455C2 (uk) Похідні індолу як протиракові агенти
TR201819805T4 (tr) Flavaglin türevleri̇.